LO leadership has developed a new R&D strategy designed to maximize our current assets, efficiently develop new ones, and deliver breakthrough medicines for patients. Sue Mahony sat down with us to share how it all comes together.
Why is the time right for an updated strategy?
This is an exciting time to be in oncology. The pace of innovation has picked up, leading to rapid scientific advances that are pushing us to a new frontier. At the same time, the bar for success continues to rise; patients, physicians, regulators and payers are demanding more than incremental advances, and we must deliver.
Lilly can meet and even exceed this bar. We can win in oncology, and in order to do so, we must remain relentless in our pursuit of developing and delivering transformative medicines that make a meaningful difference to patients and the physicians who treat them.
Which part of the strategy are you most enthusiastic about?
The idea of foundational agents and regimens is really exciting. These medicines are rooted in tumor biology, can target a number of different cancers, and offer tremendous promise in changing how we think about the disease and how to treat it. These foundational elements offer the best chance to provide breakthrough therapies that target cancer at its very core; they can truly redefine state-of-the-art cancer care. Based on this approach, we’ve got products launching or nearly ready to launch that target some of the greatest areas of unmet need – in cancers where there really are not great options for patients today.
What this means to our own colleagues, is that regardless of your function, you will either be discovering, developing or bringing to market medicines that have the potential to change the landscape of some of the most challenging and complex cancers of our time. What this could mean for patients and their loved ones is what inspires me.
What do you see as the employee role in creating and sustaining meaningful change to make this new strategy a reality?
The only way we can deliver on the strategy and win for patients is through the commitment of every single person on our team. We know that change is both exciting and difficult, and over the next few months we’ll be working with all the teams here to successfully implement the updated strategy – from the organizational structure, to new behaviors, and capabilities. We want to be sure that everyone here clearly sees what this new strategy means and how they can be part of this exciting future for Lilly Oncology.